Oxford, UK – 25 October 2012. Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, will host a live webinar on Thursday 15th November (3pm BST). Dr Daniel Swan, Senior NGS Computational Biologist at OGT, will discuss how RNA-Seq is revolutionising the field of transcriptomics by delivering unprecedented biological insight into the way cells function. He will also explain how this can only be reliably achieved through good experimental design — ensuring the data generated represents the true biology — and rigorous data analysis procedures.
The 45-minute webinar will be essential viewing for everyone interested in learning why RNA-Seq delivers novel biological discoveries and how best to design an NGS gene expression study that delivers true biological insight. As part of the webinar, Dr Swan will utilise OGT’s NGS data reporting interface, which makes it quick, easy and intuitive to visualise gene and transcript expression levels, identify isoforms and perform SNP and indel analysis for a range of eukaryotes.
To register for the webinar please visit the sign-up page.
For more information about OGT’s RNA-Seq, targeted sequencing and other genetic analysis services, go to www.ogt.co.uk.
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: firstname.lastname@example.org
W: www.ogt.co.uk ; Twitter: @OxfordGeneTech
About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk.
Diagnostic Biomarkers: Utilising proprietary next generation technologies, OGT is building a rich patent-protected portfolio of promising biomarkers for early-stage cancer and autoimmune disease detection. The biomarker pipeline includes advanced programmes in colorectal cancer, prostate cancer and pancreatic cancer plus the autoimmune disease systemic lupus erythematosus (SLE). OGT is currently assessing partnership opportunities to commercialise these biomarker panels.
Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high-quality genomic data to customers worldwide. OGT’s CytoSure™ cytogenetics array, labelling and interpretation software products and services provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.
CytoSure™: For research use only
This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.